Are typical starting doses of the selective serotonin reuptake inhibitors sub-optimal? A meta-analysis of randomized, double-blind, placebo-controlled, dose-finding studies in major depressive disorder

References

• Amin M, Lehmann H, Mirmiran J. A double-blind, placebo-controlled dose-finding study with sertraline. Psychopharmacol Bull 1989; 25: 164–167
   PubMedGoogle Scholar
• Bech P, Tanghoj P, Andersen HF, et al. Citalopram dose-response revisited using an alternative psychometric approach to evaluate clinical effects of four fixed citalopram doses compared to placebo in patients with major depression. Psychopharmacology (Berlin) 2002; 163: 20–25
   PubMed Web of Science ®Google Scholar
• Bech P, Tanghoj P, Cialdella P, et al. Escitalopram dose-response revisited: an alternative psychometric approach to evaluate clinical effects of escitalopram compared to citalopram and placebo in patients with major depression. Int J Neuropsychopharmacol 2004; 7: 283–290
   PubMed Web of Science ®Google Scholar
• Bech P, Andersen HF, Wade A. Effective dose of escitalopram in moderate versus severe DSM-IV major depression. Pharmacopsychiatry 2006; 39: 128–134
   PubMed Web of Science ®Google Scholar
• Burke WJ, Gergel I, Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 2002; 63: 331–336
   PubMed Web of Science ®Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177–188
   PubMed Web of Science ®Google Scholar
• Dornseif BE, Dunlop SR, Potvin JH, Wernicke JF. Effect of dose escalation after low-dose fluoxetine therapy. Psychopharmacol Bull 1989; 25: 71–79
   PubMedGoogle Scholar
• Dunlop SR, Dornseif BE, Wernicke JF, et al. Pattern analysis shows beneficial effect of fluoxetine treatment in mild depression. Psychopharmacol Bull 1990; 26: 173–180
   PubMedGoogle Scholar
• Fabre LF, Putman HP. A fixed-dose clinical trial of fluoxetine in outpatients with major depression. J Clin Psychiatry 1987; 48: 406–408
   PubMedGoogle Scholar
• Fabre LF, Abuzzahab FS, Amin M, et al. Sertraline safety and efficacy in major depression: a double-blind fixed-dose comparison with placebo. Biol Psychiatry 1995; 38: 592–602
   PubMed Web of Science ®Google Scholar
• Feighner JP, Øvero K, Multicenter. Placebo-controlled, fixed-dose study of citalopram in moderate-to-severe depression. J Clin Psychiatry 1999; 60: 824–830
   PubMed Web of Science ®Google Scholar
• Fieve RR, Goodnick PJ, Peselow ED, Barouche F, Schlegel A. Pattern analysis of antidepressant response to fluoxetine. J Clin Psychiatry 1986a; 47: 560–562
   PubMedGoogle Scholar
• Fieve RR, Goodnick PJ, Peselow E, Schlegel A. Fluoxetine response: endpoint vs pattern analysis. Int Clin Psychopharmacol 1986b; 1: 320–323
   PubMedGoogle Scholar
• Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56–62
   PubMed Web of Science ®Google Scholar
• Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials. 1996; 17: 1–12
   PubMedGoogle Scholar
• Laird NM, Mosteller F. Some statistical methods for combining experimental results. Int J Technol Assess Health Care 1990; 6: 5–30
   PubMedGoogle Scholar
• Montgomery SA, Asberg A. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382–389
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Rasmussen JG, Lyby K, et al. Dose response relationship of citalopram 20 mg, citalopram 40 mg and placebo in the treatment of moderate and severe depression. Int Clin Psychopharmacol 1992; 6(Suppl 5)65–70
   PubMedGoogle Scholar
• Mosteller F, Colditz GA. Understanding research synthesis (meta-analysis). Annu Rev Public Health 1996; 17: 1–23
   PubMed Web of Science ®Google Scholar
• Nemeroff, CB, Entsuah, R, Willard, LB, , et al. 2003. Comprehensive pooled analysis of remission data: venlafaxine vs SSRIs (compare). American Psychiatric Association Annual Meeting
   Google Scholar
• Papakostas GI, Fava M. Monoamine-based pharmacotherapy. Biology of depression: From novel insights to therapeutic strategies1st ed, J Licinio. Wiley-VCH Verlag, Weinheim 2005; 87–140
   Google Scholar
• Papakostas GI, Fava M. Does the probability of receiving placebo influence the likelihood of responding to placebo or clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. Neuropsychopharmacology 2006a; 31(Suppl 1)s158
   Google Scholar
• Papakostas GI, Schwartz TL. Pharmacotherapeutic strategies to enhance tolerability and adherence in MDD. Depression: Treatment strategies and management, TJ Petersen, TL Schwartz. Taylor & Francis, New York 2006b; 1: 201–215
   Google Scholar
• Papakostas GI, Petersen T, Denninger JW, et al. Psychosocial functioning during the treatment of major depressive disorder with fluoxetine. J Clin Psychopharmacol 2004; 24: 507–511
   PubMed Web of Science ®Google Scholar
• Paykel ES, Ramana R, Cooper Z, et al. Residual symptoms after partial remission: an important outcome in depression. Psychol Med 1995; 25: 1171–1180
   PubMed Web of Science ®Google Scholar
• Petersen T, Dording C, Neault NB, et al. A survey of prescribing practices in the treatment of depression. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26: 177–187
   PubMed Web of Science ®Google Scholar
• Petersen T, Papakostas GI, Posternak MA, et al. Empirical testing of two models for staging antidepressant treatment resistance. J Clin Psychopharmacol 2005; 25: 336–341
   PubMed Web of Science ®Google Scholar
• Schweizer E, Rickels K, Amsterdam JD, Fox I, Puzzuoli G, Weise C. What constitutes an adequate antidepressant trial for fluoxetine?. J Clin Psychiatry 1990; 51: 8–11
   PubMed Web of Science ®Google Scholar
• Trivedi MH, Pigotti TA, Perera P, et al. Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder. J Clin Psychiatry 2004; 65: 1356–1364
   PubMed Web of Science ®Google Scholar
• Walczak DD, Apter JT, Halikas JA, et al. The oral dose-effect relationship for fluvoxamine: a fixed-dose comparison against placebo in depressed outpatients. Ann Clin Psychiatry 1996; 8: 139–151
   PubMedGoogle Scholar
• Wernicke JF, Dunlop SR, Dornseif BE, et al. Fixed-dose fluoxetine therapy for depression. Psychopharmacol Bull 1987; 23: 164–168
   PubMed Web of Science ®Google Scholar
• Wernicke JF, Dunlop SR, Dornseif BE, et al. Low-dose fluoxetine therapy for depression. Psychopharmacol Bull 1988; 24: 183–188
   PubMed Web of Science ®Google Scholar